ReviewBiomolecules2026
Beyond Junk DNA: Emerging Roles of Non-Coding RNAs in Cancer and Therapeutic Innovation.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Non-coding RNAs (ncRNAs) are the biggest class of regulatory molecules in the human genome, which constitute ~98% of total transcripts, and were once considered as "transcriptional noise". This review will focus on the newly identified functions of non-coding RNAs (ncRNAs) in cancer biology and therapeutic innovations. We review the existing knowledge on microRNAs, long non-coding RNAs, and circular RNAs in the context of their different experimental and computational studies, and we highlight their mechanisms of action in cancer hallmarks such as proliferation and resistance to apoptosis, metastasis, and metabolic reprogramming. We evaluate the translational landscape of ncRNA-based therapeutics by examining clinical trials in progress and completed, delivery methods, and emerging technologies. This review aims to separate fact from fiction and offer a balanced view on the facts, which will help guide future research and clinical development in the field of ncRNA oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.